CAR-T cell therapy for myasthenia gravis shows promise in small study by Cartesian Therapeutics
Danny DeBerry was starting to lose hope. For more than a decade, the North Carolina forester had suffered from myasthenia gravis, a disease where a person’s own immune system mistakenly attacks and destroys the vital junctions between nerves and muscles.
What began as double vision problems that left him seeing two of every tree in the woods soon morphed into leg and arm weakness. A couple of years ago, he could barely walk from his house to his pickup truck without having to stop and catch his breath. Just as depression was sinking in, DeBerry read about an experimental treatment called a CAR-T cell therapy that might help him.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.